Innate immune responses to malaria liver stage infection

Information

  • Research Project
  • 9569059
  • ApplicationId
    9569059
  • Core Project Number
    R01AI114699
  • Full Project Number
    3R01AI114699-04S1
  • Serial Number
    114699
  • FOA Number
    PA-16-288
  • Sub Project Id
  • Project Start Date
    11/1/2014 - 10 years ago
  • Project End Date
    10/31/2019 - 5 years ago
  • Program Officer Name
    MO, ANNIE X Y
  • Budget Start Date
    4/18/2018 - 6 years ago
  • Budget End Date
    10/31/2018 - 6 years ago
  • Fiscal Year
    2018
  • Support Year
    04
  • Suffix
    S1
  • Award Notice Date
    4/18/2018 - 6 years ago

Innate immune responses to malaria liver stage infection

DESCRIPTION (provided by applicant): Plasmodium species, the etiologic agents of malaria, kill nearly 1 million people annually. They initially infect the liver as sporozoites, then they replicate as liver stages within hepatocytes to generate exoerythrocytic merozoites that initiate symptomatic blood stage infection. These preerythrocytic stages of infection are clinically silent and were thought to not provoke a significant innate immune response. Yet, recent findings from our group and collaborators have shown that preerythrocytic stages induce a pronounced innate immune response in the liver. The mechanisms by which these complex parasites induce an innate immune response and the downstream effects of these responses on parasite infection remain poorly defined. Understanding the innate immune response to this eukaryotic, intracellular pathogen is important in its own right but also a critical missing piece in the puzzl to understand the development of sterilizing adaptive immunity engendered by whole parasite immunizations. Therefore, we propose to identify which innate immune responses are activated by wild-type and attenuated Plasmodium preerythrocytic parasites and to determine how these innate immune responses influence protective adaptive immune responses. Using gene expression analysis and functional assays, we have shown that liver stage infection induces an innate immune response mediated by type I and type II interferon (IFN) signaling pathways. We have also shown that lymphocytes infiltrate the liver within days following infection and that this infiltration is strongly dependent on type I IFN (IFN-1) signaling. Furthermore, this innate response reduces the initial infection. These results indicate a link between IFN-1, lymphocyte recruitment, and subsequent innate parasite elimination. Our preliminary data also shows that this IFN-1 driven innate response shapes the adaptive immune response that is engendered by whole parasite immunizations. This we demonstrate with mice deficient in key IFN-1 signaling molecules, which surprisingly, are better protected by whole parasite immunizations. In this proposal, we intend to further delineate the generation and consequences of an IFN-mediated innate immune response to Plasmodium liver infection. In Aim 1 we will identify the host-parasite interactions that initiate this IFN-mediated innate immune response and identify the cell types in the liver that respond to IFN. In Aim 2 we will characterize cell-specific responses withi the liver following infection and identify cytokine and chemokine receptors that are necessary for innate lymphocyte infiltration. Additionally, we will evaluate the cellular mechanisms by which these innate cells eliminate liver stage parasites. Finally, in Aim 3, we will investigate how IFN-1-mediated signaling influences the development of adaptive immune responses engendered by whole parasite immunizations. Understanding the nature of the early innate immune response will reveal how a complex eukaryotic parasite engages early host immune defenses. Equally important, it will also identify innate molecular pathways to target for improvement of adaptive immune responses after vaccination that aims to protect against malaria infection.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    3
  • Direct Cost Amount
    27983
  • Indirect Cost Amount
    26864
  • Total Cost
    54847
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:54847\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    IHD
  • Study Section Name
    Immunity and Host Defense
  • Organization Name
    SEATTLE BIOMEDICAL RESEARCH INSTITUTE
  • Organization Department
  • Organization DUNS
    070967955
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981095240
  • Organization District
    UNITED STATES